Durable response in a patient with HER2-positive esophageal squamous cell carcinoma and diffuse liver metastases treated with chemotherapy-free anti-HER2 therapy: a case report

Esophageal cancer (EC) is among the most prevalent and lethal malignancies worldwide, particularly in China where esophageal squamous cell carcinoma (ESCC) represents the predominant histological subtype. Systemic chemotherapy plus immunotherapy remains the standard first-line treatment for advanced or metastatic ESCC; however, chemotherapy-associated toxicities frequently impair quality of life and limit treatment adherence. Human epidermal growth factor receptor 2 (HER2) is a well-established therapeutic target in gastroesophageal junction (GEJ) adenocarcinoma, with multiple anti-HER2 agents approved globally. In contrast, HER2 overexpression is rare in ESCC, and its clinical significance and optimal treatment strategy remain poorly defined, especially in patients with extensive metastatic disease. Herein, we describe a 53-year-old male patient diagnosed with HER2-positive advanced ESCC complicated by diffuse liver metastases who achieved durable response following administration of a chemotherapy-free regimen combined with anti-HER2 therapy. Notably, the patient obtained durable disease control without traditional chemotherapy, supporting the feasibility and potential benefit of chemotherapy-free anti-HER2-based strategies in this rare molecular subset. This case provides valuable real-world evidence for the clinical utility of HER2-directed therapy in HER2-positive ESCC, even in the setting of diffuse liver metastases, and highlights the potential of chemotherapy-free approaches to improve outcomes and quality of life. Further clinical investigations are warranted to validate this promising therapeutic strategy.

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2026-11-18
DOI
https://doi.org/10.3389/fmed.2026.1921440
Primary Topic
Esophageal Cancer Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Durable response in a patient with HER2-positive esophageal squamous cell carcinoma and diffuse liver metastases treated with chemotherapy-free anti-HER2 therapy: a case report

Jin Sheng, Xuxu Yu
2 links
Frontiers in Medicine
Esophageal Cancer Research and Treatment
article

Durable response in a patient with HER2-positive esophageal squamous cell carcinoma and diffuse liver metastases treated with chemotherapy-free anti-HER2 therapy: a case report

Jin Sheng, Xuxu Yu
article en

Abstract

Esophageal cancer (EC) is among the most prevalent and lethal malignancies worldwide, particularly in China where esophageal squamous cell carcinoma (ESCC) represents the predominant histological subtype. Systemic chemotherapy plus immunotherapy remains the standard first-line treatment for advanced or metastatic ESCC; however, chemotherapy-associated toxicities frequently impair quality of life and limit treatment adherence. Human epidermal growth factor receptor 2 (HER2) is a well-established therapeutic target in gastroesophageal junction (GEJ) adenocarcinoma, with multiple anti-HER2 agents approved globally. In contrast, HER2 overexpression is rare in ESCC, and its clinical significance and optimal treatment strategy remain poorly defined, especially in patients with extensive metastatic disease. Herein, we describe a 53-year-old male patient diagnosed with HER2-positive advanced ESCC complicated by diffuse liver metastases who achieved durable response following administration of a chemotherapy-free regimen combined with anti-HER2 therapy. Notably, the patient obtained durable disease control without traditional chemotherapy, supporting the feasibility and potential benefit of chemotherapy-free anti-HER2-based strategies in this rare molecular subset. This case provides valuable real-world evidence for the clinical utility of HER2-directed therapy in HER2-positive ESCC, even in the setting of diffuse liver metastases, and highlights the potential of chemotherapy-free approaches to improve outcomes and quality of life. Further clinical investigations are warranted to validate this promising therapeutic strategy.

Frontiers in MedicineVol. 13
Sir Run Run Shaw Hospital (CN), Zhejiang University (CN)
Good health and well-being
Esophageal Cancer Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon